Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Streptavidin（SA） Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD5

CD5

Brief Information

Name:T-cell surface glycoprotein CD5
Target Synonym:Epididymis Secretory Sperm Binding Protein,CD5,Lymphocyte antigen T1/Leu-1,T-cell surface glycoprotein CD5,CD5 Molecule,CD5 Antigen (P56-62),LEU1,CD5 Antigen,T1,CD5 Antigens
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CD5-HP2H6 Human PE-Labeled Human CD5 Protein, His Tag (Site-specific conjugation)
CD5-HP2H6-structure
CD5-H5253 Human Human CD5 Protein, Fc Tag (MALS verified)
CD5-H5253-structure
CD5-H5253-sds
CD5-H82F3 Human Biotinylated Human CD5 Protein, Fc,Avitag™ (MALS verified)
CD5-H82F3-structure
CD5-H82F3-sds
CD5-H82E5 Human Biotinylated Human CD5 Protein, His,Avitag™
CD5-H82E5-structure
CD5-H82E5-sds
CD5-H52H2 Human FITC-Labeled Human CD5 Protein, His Tag
CD5-H52H2-structure
CD5-H52H2-sds
CD5-H52H5 Human Human CD5 Protein, His Tag
CD5-H52H5-structure
CD5-H52H5-sds
ACRO Quality

Part of Bioactivity data

CD5-HP2H6-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-CD5 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD5, His Tag (Cat. No. CD5-HP2H6) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

Protocol
CD5-H5253-MALS-HPLC
Human CD5, Fc Tag (Cat. No. ) MALS images

The purity of Human CD5, Fc Tag (Cat. No. CD5-H5253) is more than 90% and the molecular weight of this protein is around 145-165 kDa verified by SEC-MALS.

Report
  • Background
    T-cell surface glycoprotein CD5 is also known as Lymphocyte antigen T1/Leu-1 and LEU1,which is phosphorylated on tyrosine residues by LYN,so CD5 can create binding sites for PTPN6/SHP-1.CD5 may act as a receptor in regulating T-cell proliferation. CD5 is expressed at various developmental and activation stages on human B cells.CD5 is a well established negative regulator of TCR and BCR signalling.CD5-positive cells may also prevent the emergence of autoimmunity by provision of cytokines such as IL-10. Development,selection and function of different B- and T-cell subsets or their preferential survival may be directly or indirectly dependent on different glycan structures associated with CD5 or CD5-like molecules.
  • Clinical and Translational Updates
      

  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    CD5-H82F3-MALS-HPLC
    Biotinylated Human CD5, Fc,Avitag (Cat. No. ) MALS images

    The purity of Biotinylated Human CD5, Fc,Avitag (Cat. No. CD5-H82F3) is more than 90% and the molecular weight of this protein is around 155-175 kDa verified by SEC-MALS.

    Report

Synonym Name

CD5,LEU1

Background

T-cell surface glycoprotein CD5 is also known as Lymphocyte antigen T1/Leu-1 and LEU1,which is phosphorylated on tyrosine residues by LYN,so CD5 can create binding sites for PTPN6/SHP-1.CD5 may act as a receptor in regulating T-cell proliferation. CD5 is expressed at various developmental and activation stages on human B cells.CD5 is a well established negative regulator of TCR and BCR signalling.CD5-positive cells may also prevent the emergence of autoimmunity by provision of cytokines such as IL-10. Development,selection and function of different B- and T-cell subsets or their preferential survival may be directly or indirectly dependent on different glycan structures associated with CD5 or CD5-like molecules.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD5 CAR T (CT125B) therapy ( Beijing Boren Hospital) CD5 CAR T (CT125B); CT125B; CD5 CAR T Phase 1 Clinical Beijing Gao Boren Hospital Co Ltd Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
CT-125A CT-125A; RD-125 Phase 1 Clinical Nanjing Iaso Biotherapeutics Co Ltd Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD5 CAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
MT-101 MT-101 Phase 2 Clinical Myeloid Therapeutics Inc Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides Details
CD5 CAR-T Therapy(Xuanwu Hospital) Phase 1 Clinical Xuanwu Hospital Of Capital Medical University Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap